Conditions and Treatments
- Harold Snyder Family Professor of Cardiology, Department of Medicine
- Associate Director, Leon H Charney Division of Cardiology, Department of Medicine
- Senior Associate Dean for Clinical Sciences
- Co-Director, Clinical and Translational Science Institute
- Director, Cardiovascular Clinical Research Center
- American Board of Internal Medicine (Cardiovascular Disease), 1983
- American Board of Internal Medicine - Internal Medicine, 1980
Education and Training
- Fellowship, Johns Hopkins Hospital, Medicine/Cardiology, 1982
- Residency, Peter Bent Brigham Hospital, Medicine, 1980
- MD from Harvard University, 1977
Locations and Appointments
Research My Research
Over the past several decades, clinical research activities in the Division of Cardiology have contributed substantially to the cardiovascular literature and have greatly influenced the practice of clinical cardiology. In 2003 the Cardiovascular Clinical Research Center (CCRC) was established under the direction of Dr. Judith Hochman. Considered one of the world's leading cardiovascular clinical trialists, Dr. Hochman's studies in the areas of cardiogenic shock and coronary artery disease have transformed the guidelines for treating patients with heart disease. The CCRC serves as the clinical coordinating center for international and national multi-center trials and as the organizing entity for numerous local trials as well. The CCRC has helps support participant enrollment in a wide range of clinical trials and has helped administer the division's expanding portfolio of clinical research.
Dr. Hochman is Senior Associate Dean for Clinical Sciences, Co-Director of the NYU-HHC Clinical and Translational Science Institute, Harold Snyder Family Professor and Associate Director of the Leon Charney Division of Cardiology, and Director of the Cardiovascular Clinical Research Center (CCRC) [http://medicine.med.nyu.edu/cardiology/cardiovascular-clinical-research-center-ccrc] at the New York University School of Medicine. Her particular areas of interest include the management of ischemic heart disease, both acute and chronic, with a special interest in the role of revascularization with either PCI or CABG, the pathophysiology and management of cardiogenic shock, and optimized management based on sex differences. She is currently the Study Chair of the ISCHEMIA Trial, an NHLBI/NIH-funded multicenter randomized clinical trial, which will compare two strategies for the management of patients with stable coronary artery disease: routine invasive management with the intent to revascularize using contemporary PCI or CABG plus optimal medical therapy, versus routine optimal medical therapy alone, with cardiac catheterization reserved for refractory symptoms or an acute ischemic event. She was the Study Chair of the NHLBI-funded Occluded Artery Trial (OAT), which tested the hypothesis that late opening of the infarct related artery (PCI/stent) will reduce the risk of death, MI and Class IV HF. OAT demonstrated no benefit for late angioplasty for persistent total occlusion late post MI and a trend toward excess reinfarction and led to new recommendations against performing this procedure in the ACC/AHA Guidelines (NSTEMI and STEMI, PCI) and the 2008 European Society of Cardiology Guidelines. These findings proved durable over the long- term (>6 years). In a subset of patients in the NHLBI-funded angiographic OAT ancillary study (TOSCA 2) less LV remodeling was seen with PCI. However, the NHLBI-funded myocardial viability ancillary study did not confirm that and importantly, the presence of retained viability in the zone supplied by the infarct-related artery did not correlate with improvement in EF or LV size with PCI. Patients in both the PCI and medical therapy only groups had significant improvement in EF over one year, with no difference between the groups.
She was the Study Chair of the NHLBI-funded SHOCK Trial, which demonstrated a one year and long-term durable survival benefit for emergency PCI or CABG and led to a change in the US and European guidelines. She has investigated the role of systemic inflammation and excess nitric oxide in the genesis and persistence of cardiogenic shock and was Study Chair for phase 2 and phase 3 studies of nitric oxide synthase inhibition in refractory cardiogenic shock- SHOCK 2 and TRIUMPH. Dr. Hochman has served on numerous steering and executive committees for multi-center ischemic heart disease clinical trials including MAGIC, APEX-AMI, SOLID-TIMI 52, STABILITY, TRILOGY, and EARLY ACS. She has served as a member and chair of numerous Data and Safety Monitoring Boards (DSMBs) on trials sponsored by NIH and industry. In recognition of her scientific contributions she was awarded the 2014 AHA Clinical Research Prize and the 2016 ACC Distinguished Scientist Award (Clinical Domain).
Research Interests Timeline
Journal of the American College of Cardiology. 2018 Jun 05; 71(22):2552-2554
Circulation. Cardiovascular quality & outcomes. 2018 May; 11(5):e004791-e004791